# Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer

> **NCT07490509** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Poitiers University Hospital** · enrollment: 235 (estimated)

## Conditions studied

- Abemaciclib
- Abemaciclib-related Diarrhea
- Breast Cancer

## Interventions

- **BIOLOGICAL:** Blood samples for PK
- **OTHER:** Questionnaire

## Key facts

- **NCT ID:** NCT07490509
- **Lead sponsor:** Poitiers University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2029-04
- **Final completion:** 2029-04
- **Target enrollment:** 235 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07490509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07490509, "Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07490509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*